Loading page…
Healthcare
Alnylam Pharmaceuticals, Inc. records an AlphaScore of 61/100 in the Healthcare sector as of October 11, 2026. A major strength is its exceptional revenue growth of 65.19% and a high growth sub-score of 97, while a key risk is its elevated price-to-earnings (pe) ratio of 39.24. The stock is priced at $232.68 with a market capitalization of $31.13 billion. Additional fundamentals show a forward pe of 18.73, a strong return on equity (roe) of 39.76%, and a gross margin of 81.77%. The net margin stands at 8.45% with no dividend paid. Evidence is limited to the provided record.
Written 11/10/2026, 00:32:44 UTC · Snapshot 11/10/2026